Next Article in Journal
Lack of Sex Disparity in Oral Anticoagulation in Atrial Fibrillation Patients Presenting with Ischemic Stroke in a Rural Population
Previous Article in Journal
Occurrence, Trends, Management and Outcomes of Patients Hospitalized with Clinically Suspected Myocarditis—Ten-Year Perspectives from the MYO-PL Nationwide Database
Previous Article in Special Issue
Association of Body Composition and Sarcopenia with NASH in Obese Patients
Review

Defining NASH from a Multi-Omics Systems Biology Perspective

1
Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark
2
Department of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, 82152 Martinsried, Germany
3
Systems Medicine, Steno Diabetes Center Copenhagen, 2820 Gentofte, Denmark
4
Center for Health Data Science, University of Copenhagen, 2200 Copenhagen, Denmark
5
Big Data Institute, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7LF, UK
6
Department of Clinical Biochemistry, Rigshospitalet, 2100 Copenhagen, Denmark
7
Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark
8
Functional Proteomics, Jena University Hospital, 07747 Jena, Germany
*
Author to whom correspondence should be addressed.
Academic Editor: Ragai R Mitry
J. Clin. Med. 2021, 10(20), 4673; https://doi.org/10.3390/jcm10204673
Received: 30 June 2021 / Revised: 1 October 2021 / Accepted: 8 October 2021 / Published: 12 October 2021
(This article belongs to the Special Issue Challenges in Nonalcoholic Steatohepatitis)
Non-alcoholic steatohepatitis (NASH) is a chronic liver disease affecting up to 6.5% of the general population. There is no simple definition of NASH, and the molecular mechanism underlying disease pathogenesis remains elusive. Studies applying single omics technologies have enabled a better understanding of the molecular profiles associated with steatosis and hepatic inflammation—the commonly accepted histologic features for diagnosing NASH, as well as the discovery of novel candidate biomarkers. Multi-omics analysis holds great potential to uncover new insights into disease mechanism through integrating multiple layers of molecular information. Despite the technical and computational challenges associated with such efforts, a few pioneering studies have successfully applied multi-omics technologies to investigate NASH. Here, we review the most recent technological developments in mass spectrometry (MS)-based proteomics, metabolomics, and lipidomics. We summarize multi-omics studies and emerging omics biomarkers in NASH and highlight the biological insights gained through these integrated analyses. View Full-Text
Keywords: biomarker discovery; liver disease; machine learning; multi-omics; NAFLD; systems biology biomarker discovery; liver disease; machine learning; multi-omics; NAFLD; systems biology
Show Figures

Figure 1

MDPI and ACS Style

Niu, L.; Sulek, K.; Vasilopoulou, C.G.; Santos, A.; Wewer Albrechtsen, N.J.; Rasmussen, S.; Meier, F.; Mann, M. Defining NASH from a Multi-Omics Systems Biology Perspective. J. Clin. Med. 2021, 10, 4673. https://doi.org/10.3390/jcm10204673

AMA Style

Niu L, Sulek K, Vasilopoulou CG, Santos A, Wewer Albrechtsen NJ, Rasmussen S, Meier F, Mann M. Defining NASH from a Multi-Omics Systems Biology Perspective. Journal of Clinical Medicine. 2021; 10(20):4673. https://doi.org/10.3390/jcm10204673

Chicago/Turabian Style

Niu, Lili, Karolina Sulek, Catherine G. Vasilopoulou, Alberto Santos, Nicolai J. Wewer Albrechtsen, Simon Rasmussen, Florian Meier, and Matthias Mann. 2021. "Defining NASH from a Multi-Omics Systems Biology Perspective" Journal of Clinical Medicine 10, no. 20: 4673. https://doi.org/10.3390/jcm10204673

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop